January 5, 2017 / 3:15 PM / 7 months ago

BRIEF-Takeda and PvP Biologics announce development agreement for celiac disease

Jan 5 (Reuters) - Takeda Pharmaceutical Co Ltd :

* Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for development of Kumamax

* Under terms of agreement, PvP will conduct research, development through phase 1 proof-of-principle studies

* To fund $35 million for PvP's expenses related to plan in exchange for option to acquire PvP following receipt of pre-defined data package

* Takeda may exercise its option to acquire PvP by paying an undisclosed fee as well as development and regulatory milestones Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below